Profile data is unavailable for this security.
About the company
APEX BIOTECHNOLOGY CORP is a Taiwan-based company principally engaged in the research, development, manufacture and distribution of testing strips, electrode testing strips and tester suites. The Company primarily provides testing strips and monitoring systems, including blood glucose monitoring systems, uric acid monitoring systems, pesticide residue detection systems, lactate monitoring systems and hemachrome testing systems, among others. Its blood glucose monitoring systems and uric acid monitoring systems are mainly used by patients, doctors and nurses in hospitals and clinics. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and the rest of Asia.
- Revenue in TWD (TTM)1.68bn
- Net income in TWD115.78m
- Incorporated1997
- Employees641.00
- LocationApex Biotechnology CorpNo. 7Li-Hsin Road V, Hsinchu Science ParkHSINCHU 300TaiwanTWN
- Phone+886 35641952
- Fax+886 35678302
- Websitehttps://www.apexbio.com.tw/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apex Biotechnology Corp. | 1.68bn | 115.78m | 3.43bn | 641.00 | 29.73 | 1.91 | 17.91 | 2.04 | 1.15 | 1.15 | 16.71 | 17.97 | 0.6969 | 1.54 | 4.38 | -- | 4.81 | 5.41 | 6.00 | 7.24 | 31.68 | 26.54 | 6.90 | 6.89 | 1.98 | -- | 0.0787 | 84.56 | -25.29 | -3.88 | -36.31 | 4.01 | -21.20 | 5.35 |
| Chunghwa Chemical Synthsis&Biotech CoLtd | 2.09bn | 264.91m | 3.57bn | 243.00 | 13.48 | 1.06 | 7.84 | 1.71 | 3.41 | 3.41 | 26.83 | 43.20 | 0.4286 | 1.31 | 7.59 | -- | 5.44 | 9.03 | 6.39 | 10.56 | 36.30 | 43.26 | 12.70 | 20.15 | 0.6937 | -- | 0.265 | 24.83 | -1.45 | 15.40 | -43.14 | 2.49 | 36.95 | -7.79 |
| OK Biotech Co Ltd | 1.19bn | 2.95m | 3.78bn | 62.00 | 532.85 | 1.58 | 51.15 | 3.17 | 0.0487 | 0.0487 | 8.72 | 16.45 | 0.389 | 2.44 | 2.92 | -- | -0.052 | 3.06 | -0.0675 | 4.08 | 16.52 | 20.27 | -0.1337 | 6.01 | 1.60 | -2.97 | 0.1217 | 118.40 | -19.65 | 1.25 | -97.95 | -55.09 | 72.81 | -31.15 |
| Phytohealth Corp | 162.49m | -47.12m | 4.01bn | 84.00 | -- | 2.06 | -- | 24.69 | -0.2372 | -0.2372 | 0.8181 | 9.80 | 0.0689 | 0.6035 | 5.31 | -- | -3.15 | -5.66 | -3.82 | -7.31 | 41.63 | 47.70 | -45.63 | -92.91 | 23.29 | -- | 0.0122 | -- | 19.95 | 8.62 | 40.67 | -- | -39.46 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.33m | 1.33% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 97.18k | 0.10% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 70.00k | 0.07% |
| LGT Capital Partners AG (Investment Management)as of 31 May 2023 | 6.00k | 0.01% |
| DFA Australia Ltd.as of 31 Dec 2023 | 5.12k | 0.01% |
